Semaglutide / GLP-1 Therapy

What Semaglutide and GLP-1 Therapy Are

Semaglutide is a GLP-1 receptor agonist, a class of medications that mimic glucagon-like peptide-1, a hormone the gut naturally releases after eating. Originally developed to treat type 2 diabetes, this class is now widely used for chronic weight management and metabolic health. Semaglutide is delivered as a once-weekly subcutaneous injection, and a related oral formulation exists. Other medications in or adjacent to this class include liraglutide (a daily GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist).

At ENNU Life, GLP-1 therapy is used as one tool within a broader metabolic and longevity program — not as a standalone fix. It is most effective when paired with nutrition, resistance training, sleep optimization, and ongoing clinical monitoring.

How GLP-1 Therapy Works

GLP-1 receptor agonists act through several well-established mechanisms:

• Appetite regulation: They act on receptors in the brain (including the hypothalamus) that govern satiety and hunger, reducing appetite and food intake.
• Slowed gastric emptying: Food leaves the stomach more slowly, which prolongs the feeling of fullness after meals.
• Glucose-dependent insulin secretion: They stimulate insulin release from the pancreas when blood glucose is elevated, and suppress glucagon — improving blood sugar control with a low intrinsic risk of hypoglycemia when used alone.

The net clinical effect for most patients is reduced caloric intake, improved glycemic control, and meaningful weight reduction over months of consistent use.

Who May Be a Candidate

GLP-1 therapy is generally considered for adults managing weight and metabolic health, particularly those with:

• Obesity, or overweight status accompanied by a weight-related condition such as type 2 diabetes, prediabetes, hypertension, or dyslipidemia
• Difficulty achieving durable weight loss through diet and exercise alone
• Metabolic markers a clinician wants to improve, evaluated through bloodwork such as fasting glucose, HbA1c, and a lipid panel

A licensed clinician determines candidacy based on your full medical history, current medications, and lab results. GLP-1 therapy is not appropriate for everyone. It is generally avoided in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and is not used during pregnancy. A history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or certain eating disorders requires careful clinical evaluation before starting.

What Treatment and Optimization Look Like

GLP-1 therapy is typically started at a low dose and increased gradually over several weeks. This dose titration is intentional: it allows the body to adjust and helps minimize gastrointestinal side effects. The maintenance dose is individualized based on response and tolerability.

A well-run program emphasizes more than the number on the scale:

• Protein intake and resistance training to preserve lean muscle mass during weight loss
• Periodic lab monitoring of metabolic markers to confirm the therapy is improving your underlying health
• Regular clinical follow-up to adjust dosing, manage side effects, and reassess goals
• A long-term plan, since weight regain is common after stopping; your clinician should discuss maintenance strategy from the outset

Side Effects and Safety Considerations

The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal discomfort — and tend to be most noticeable when starting therapy or increasing the dose. They often ease over time and can be reduced with slower titration, smaller meals, and adequate hydration. Less common but important risks discussed in this medication class include pancreatitis, gallbladder problems, and dehydration-related effects. Anyone experiencing severe or persistent abdominal pain should seek prompt medical evaluation. Your clinician will review your complete medication list, because GLP-1 therapy can affect the absorption and dosing of other drugs.

Next Steps

If you’re considering GLP-1 therapy for weight management or metabolic health, the right first step is a clinical evaluation that reviews your history, goals, and bloodwork so a licensed provider can determine whether this treatment fits you.

Start your ENNU Life health assessment

Educational only, not medical advice; consult a licensed clinician. This page does not establish a patient-provider relationship, and treatment decisions, dosing, and candidacy must be individualized by a licensed clinician who has evaluated your complete medical history.